7191-70-0

Basic information

• Product Name: 1-N-[(4-fluorophenyl)methyl]benzene-1,2-diamine
• Synonyms: 1-N-[(4-fluorophenyl)methyl]benzene-1,2-diamine;AKOS AKM00867;N-[(4-FLUOROPHENYL)METHYL]-1,2-BENZENEDIAMINE
• CAS NO: 7191-70-0
• Molecular Formula: C₁₃H₁₃FN₂
• Molecular Weight: 216.258
• Mol File: 7191-70-0.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-N-[(4-fluorophenyl)methyl]benzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-[(4-fluorophenyl)methyl]benzene-1,2-diamine(7191-70-0)
• EPA Substance Registry System: 1-N-[(4-fluorophenyl)methyl]benzene-1,2-diamine(7191-70-0)

Safety Data

• Hazardous Substances Data: 7191-70-0(Hazardous Substances Data)

Usage

General Description

1-N-[(4-fluorophenyl)methyl]benzene-1,2-diamine is a chemical compound with the molecular formula C15H15FN2. It is commonly used in the pharmaceutical industry as a starting material for the synthesis of various drugs and pharmaceutical products. 1-N-[(4-fluorophenyl)methyl]benzene-1,2-diamine is a diamine derivative containing a fluorophenyl group and a benzene ring. It has potential applications in the treatment of various medical conditions such as cancer, bacterial infections, and other diseases. Additionally, it is used in research and development for the creation of new and improved drugs. However, it is important to handle this compound with caution due to its potential toxicity and reactivity.

Upstream product

• 100460-79-5 N-(4''-fluorobenzyl)-2-nitroaniline 
• 95-54-5 1,2-diamino-benzene 
• 459-46-1 4-Fluorobenzyl bromide 
• 140-75-0 para-fluorobenzylamine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 88-74-4 2-nitro-aniline 
• 352-11-4 1-chloromethyl-4-fluorobenzene 

Downstream Products

• 84501-68-8 ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate 
• 7191-71-1 2-(chloromethyl)-1-(4-fluorobenzyl)-1H-benzo[d]imidazole 
• 84946-20-3 2-chloro-1-(4-fluorobenzyl)-1H-benzimidazole 
• 98088-84-7 1-(4-fluorobenzyl)-N-(1-phenethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 
• 73734-75-5 N-(1-cinnamylpiperidin-4-yl)-1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-amine 
• 142617-98-9 1-(4-fluorophenylmethyl)-2-(1-piperazinyl)-1H-benzimidazole 
• 75970-64-8 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine dihydrobromide 

Relevant articles and documents

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction

Disruption of EZH2-embryonic ectoderm development (EED) protein-protein interaction (PPI) is a new promising cancer therapeutic strategy. We have previously reported the discovery of astemizole, a small-molecule inhibitor targeting the EZH2-EED PPI. Herein, we report the cocrystal structure of EED in complex with astemizole at 2.15 ?. The structure elucidates the detailed binding mode of astemizole to EED and provides a structure-guided design for the discovery of a novel EZH2-EED interaction inhibitor, DC-PRC2in-01, with an affinityKdof 4.56 μM. DC-PRC2in-01 destabilizes the PRC2 complex, thereby leading to the degradation of PRC2 core proteins and the decrease of global H3K27me3 levels in cancer cells. The proliferation of PRC2-driven lymphomas cells is effectively inhibited, and the cell cycle is arrested in the G0/G1 phase. Together, these data demonstrate that DC-PRC2in-01 could be an effective chemical probe for investigating the PRC2-related physiology and pathology and providing a promising chemical scaffold for further development.

Synthesis of Structurally Diverse Benzotriazoles via Rapid Diazotization and Intramolecular Cyclization of 1,2-Aryldiamines

An operationally simple method has been developed for the preparation of N-unsubstituted benzotriazoles by diazotization and intramolecular cyclization of a wide range of 1,2-aryldiamines under mild conditions, using a polymer-supported nitrite reagent and p-tosic acid. The functional group tolerance of this approach was further demonstrated with effective activation and cyclization of N-alkyl, -aryl, and -acyl ortho-aminoanilines leading to the synthesis of N1-substituted benzotriazoles. The synthetic utility of this one-pot heterocyclization process was exemplified with the preparation of a number of biologically and medicinally important benzotriazole scaffolds, including an α-amino acid analogue.

Discovery of Benzimidazole–Quinolone Hybrids as New Cleaving Agents toward Drug-Resistant Pseudomonas aeruginosa DNA

A series of benzimidazole–quinolone hybrids as new potential antimicrobial agents were designed and synthesized. Bioactive assays indicated that some of the prepared compounds exhibited potent antibacterial and antifungal activities. Notably, 2-fluorobenzyl derivative 5 b (ethyl 7-chloro-6-fluoro-1-[[1-[(2-fluorophenyl)methyl]benzimidazol-2-yl]methyl]-4-oxo-quinoline-3-carboxylate) showed remarkable antimicrobial activity against resistant Pseudomonas aeruginosa and Candida tropicalis isolated from infected patients. Active molecule 5 b could not only rapidly kill the tested strains, but also exhibit low toxicity toward Hep-2 cells. It was more difficult to trigger the development of bacterial resistance of P. aeruginosa against 5 b than that against norfloxacin. Molecular docking demonstrated that 5 b could effectively bind with topoisomerase IV–DNA complexes, and quantum chemical studies theoretically elucidated the good antimicrobial activity of compound 5 b. Preliminary experimental reaction mechanism exploration suggested that derivative 5 b could not intercalate into DNA isolated from drug-resistant P. aeruginosa, but was able to cleave DNA effectively, which might further block DNA replication to exert powerful bioactivities. In addition, compound 5 b is a promising antibacterial agent with membrane disruption abilities.